Suresh Vedantham

Dr. Suresh Vedantham


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in American Heart Journal
Verified
Journal Article
Closed access
SVSuresh Vedantham
Suresh Vedantham
SGSamuel Z. Goldhaber
Samuel Z. Goldhaber
SKSusan R. Kahn
Susan R. Kahn
JJJim Julian
Jim Julian
EMElizabeth Magnuson
Elizabeth Magnuson
CKClive Kearon
Clive Kearon

1 September 2014 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
SVSuresh Vedantham
Suresh Vedantham
ASAkhilesh K. Sista
Akhilesh K. Sista
SKSeth J. Klein
Seth J. Klein
LNLina Nayak
Lina Nayak
MRMahmood K. Razavi
Mahmood K. Razavi
BNBoris Nikolic
Boris Nikolic

1 October 2002 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
SVSuresh Vedantham
Suresh Vedantham
TVThomas M. Vesely
Thomas M. Vesely
NPNaveen Parti
Naveen Parti
MDMichael Darcy
Michael Darcy
DHDavid M. Hovsepian
David M. Hovsepian
DPDaniel Picus
Daniel Picus

10 December 2014 in Vascular Medicine
Verified
Journal Article
Open access
JBJeffrey Birn
Jeffrey Birn
SVSuresh Vedantham
Suresh Vedantham
Acute and chronic venous disorders of the lower extremities affect millions of people and cause substantial disability. Long ago, surgeons and pathologists identified the presence of ‘spur-like’ abnormalities of the left common iliac vein; these abnormalities were hypothesized to result from compression and/or irritation from the adjacent crossing right common iliac artery. In the 1990s, physicians, starting to perform catheter-directed thrombolysis to treat extensive deep vein thrombosis (DVT), observed that about 50% of patients had an iliac vein stenosis. Vascular physicians have become aware of the occasional patient with otherwise-unexplained extremity swelling and/or pain but without a DVT history who is subsequently found to have an iliac vein abnormality. These ‘lesions’ have been hypothesized to elevate ambulatory venous pressures and thereby produce lower-extremity symptoms, increase the risk of initial and recurrent DVT episodes, and increase the risk of treatment failure with medical and endovascular therapies for thrombotic and non-thrombotic venous conditions. As a result, many practitioners now actively seek iliac venous obstructive ‘lesions’ when evaluating patients with known or suspected venous disease. However, for many patients, it continues to be unclear what degree of obstruction to venous blood flow is being caused by such lesions, how clinically significant they are, how much emphasis should be placed on identifying them, and when they should be treated. This article seeks to improve the knowledge base of vascular practitioners who make clinical decisions about the diagnosis and treatment of obstructive iliac vein lesions.

1 June 2004 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
SVSuresh Vedantham
Suresh Vedantham
TVThomas M. Vesely
Thomas M. Vesely
GSGregorio A. Sicard
Gregorio A. Sicard
DBDaniel Brown
Daniel Brown
BRBrian Rubin
Brian Rubin
DPDaniel Picus
Daniel Picus

16 January 2016 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Open access
PDF file
SVSuresh Vedantham
Suresh Vedantham
GPGregory Piazza
Gregory Piazza
ASAkhilesh K. Sista
Akhilesh K. Sista
NGNeil A. Goldenberg
Neil A. Goldenberg
Patients with venous thromboembolism (VTE) are prone to the development of both short-term and long-term complications that can substantially affect their functional capacity and quality of life. Patients with deep vein thrombosis (DVT) often develop recurrent VTE or the post-thrombotic syndrome, whereas patients with pulmonary embolism (PE) can develop long-term symptoms and functional limitations along a broad spectrum extending to full-blown chronic thromboembolic pulmonary hypertension. Clinicians who care for patients showing severe clinical manifestations of DVT and PE are often faced with challenging decisions concerning whether and how to escalate to more aggressive treatments such as those involving the use of thrombolytic drugs. The purpose of this chapter is to provide guidance on how best to individualize care to these patients.